Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > Zero enrollment update

<< Previous

Bullboard Posts

Next >>

Post by hmmmmmmmmon Mar 09, 2023 1:49pm

799 Views

Post# 35328634

Zero enrollment update

So we have to imagine it's because zero patients have been enrolled.

Back in August they told us 4 trial sites would be added by end of 2022. And they said 20 would be enrolling by the end of this month.

No matter how tiny the pledge- Seto and Kellum seem to find a way to come up well short.

PS I wonder if Kellum had to be given extra performance options to shoehorn in schlocky adjectives like "acclerate", "rapidly" and "swiftly" to describe a stalled trial?

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China